Olema Pharmaceuticals, Inc. (OLMA) SEC Filings & Earnings Calls

Board composition change may signal governance transition, but no disagreement noted.

“Resignation effective immediately; no reason given beyond personal decision.”

Pre-revenue clinical-stage company with increasing losses

“Net loss for the three months ended June 30, 2026 was $63.2 million compared to $43.8 million for the same period in 2025.”

Dependence on lead product candidate palazestrant and KAT6 inhibitor

“The Company's wholly-owned, lead product candidate, palazestrant (OP-1250), is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor antagonist and selective ER degrader.” · word for word

Clinical trial failure risk remains high; no approved products.

“Clinical-stage biopharmaceutical company with no approved products; Phase 3 data expected Q1 2027.”

Increasing cash burn rate may require future financing.

“Net loss increased to $63.2M from $43.8M; cash $461.1M.”

Clinical trial risk; no guarantee of success in Phase 1b/2 study.

“Item 8.01: Forward-looking statements caution about risks and uncertainties.”

Early-stage data; limited sample size and need for further validation.

“Item 8.01: Data from 32 patients in Phase 1, forward-looking statements caution.”

Clinical Trial Failure Risk

“The Company is a clinical-stage biopharmaceutical company with no approved products; palazestrant and OP-3136 require extensive clinical testing and regulatory approval.” · word for word

High Cash Burn Rate

“Net cash used in operating activities was $46.0 million in Q1 2026, up from $44.0 million in Q1 2025.”

Accumulated Deficit

“Accumulated deficit of $650.6 million as of March 31, 2026.”

Clinical trial risk: OPERA-01 and OPERA-02 results are binary events; failure would significantly impact the company.

“Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll” · word for word

Regulatory risk: Palazestrant NDA approval is uncertain and could be delayed or denied.

“Palazestrant has been granted FDA Fast Track designation but no guarantee of approval”

Long-term lease commitment of $18.5M, increasing fixed costs.

“Item 1.01: Total base rent for Phase I and II during Initial Term.”

Pre-revenue clinical-stage biotech with no approved products

“Company is pre-commercial; net loss of $162M in 2025.”

Key executive departure (COO) could disrupt operations

“Mr. Kovacs departed from the Company on January 30, 2026.” · word for word

High dilution risk from equity compensation and future offerings

“87.3M shares outstanding; 14.4M options outstanding; 6.0M shares available for future grant.”

No material risk; routine board appointment.

“standard form of indemnification agreement; no transactions requiring disclosure.”

Clinical trial risk: OPERA-01 and OPERA-02 pivotal trials may fail to meet endpoints

“Phase 3 OPERA-01 top-line data expected fall 2026; no efficacy data yet”

Cash burn rate: net loss of $162.5M in FY2025; cash runway may be limited

“Net loss $162.5M; cash $505.4M; R&D spend increasing”

No approved products; pre-revenue

“We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.” · word for word

Substantial additional capital needed

“We require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our research and drug development programs.” · word for word

Clinical trial failure risk

“Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.” · word for word

Dependence on single lead candidate

“We are substantially dependent on the success of our lead product candidate, palazestrant, which is currently in clinical development.” · word for word

Key financial officer departure may disrupt financial operations and investor confidence.

“Departure of COO/CFO; CEO assumes interim CFO role.”

Potential dilution from equity offering.

“Underwriting agreement filed for equity offering.”

Cash burn acceleration

“Net cash used in operating activities (108,389) (78,067)” · word for word

No revenue, pre-commercial

“The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond.” · word for word

Dilution risk from pre-funded warrants

“This number does not include 17,094,163 shares of common stock issuable upon the exercise of pre-funded warrants” · word for word

Clinical trial risk; no approved products.

“Clinical-stage biopharmaceutical company; no approved products.”